Literature DB >> 22123061

The impact of glycosylation on monoclonal antibody conformation and stability.

Kai Zheng1, Christopher Bantog, Robert Bayer.   

Abstract

Antibody glycosylation is a common post-translational modification and has a critical role in antibody effector function. The use of glycoengineering to produce antibodies with specific glycoforms may be required to achieve the desired therapeutic efficacy. However, the modified molecule could have unusual behavior during development due to the alteration of its intrinsic properties and stability. In this study, we focused on the differences between glycosylated and deglycosylated antibodies, as aglycosyl antibodies are often chosen when effector function is not desired or unimportant. We selected three human IgG1 antibodies and used PNGase F to remove their oligosaccharide chains. Although there were no detected secondary or tertiary structural changes after deglycosylation, other intrinsic properties of the antibody were altered with the removal of oligosaccharide chains in the Fc region. The apparent molecular hydrodynamic radius increased after deglycosylation based on size-exclusion chromatography analysis. Deglycosylated antibodies exhibited less thermal stability for the CH2 domain and less resistance to GdnHCl induced unfolding. Susceptibility to proteolytic cleavage demonstrated that the deglycosylated version was more susceptible to papain. An accelerated stability study revealed that deglycosylated antibodies had higher aggregation rates. These changes may impact the development of aglycosyl antibody biotherapeutics.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22123061      PMCID: PMC3242843          DOI: 10.4161/mabs.3.6.17922

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  39 in total

1.  The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms.

Authors:  Y Mimura; S Church; R Ghirlando; P R Ashton; S Dong; M Goodall; J Lund; R Jefferis
Journal:  Mol Immunol       Date:  2000 Aug-Sep       Impact factor: 4.407

2.  Global antibody development trends.

Authors:  Janice M Reichert
Journal:  MAbs       Date:  2009 Jan-Feb       Impact factor: 5.857

3.  Design of therapeutic proteins with enhanced stability.

Authors:  Naresh Chennamsetty; Vladimir Voynov; Veysel Kayser; Bernhard Helk; Bernhardt L Trout
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-01       Impact factor: 11.205

Review 4.  Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action.

Authors:  Royston Jefferis
Journal:  Trends Pharmacol Sci       Date:  2009-06-22       Impact factor: 14.819

5.  Aggregation-prone motifs in human immunoglobulin G.

Authors:  Naresh Chennamsetty; Bernhard Helk; Vladimir Voynov; Veysel Kayser; Bernhardt L Trout
Journal:  J Mol Biol       Date:  2009-06-13       Impact factor: 5.469

6.  High throughput thermostability screening of monoclonal antibody formulations.

Authors:  Feng He; Sabine Hogan; Ramil F Latypov; Linda O Narhi; Vladimir I Razinkov
Journal:  J Pharm Sci       Date:  2010-04       Impact factor: 3.534

Review 7.  IgG Fc receptors.

Authors:  J V Ravetch; S Bolland
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

8.  Structural stability of hepatitis C virus envelope glycoprotein E1: effect of pH and dissociative detergents.

Authors:  Feng He; Sangeeta B Joshi; Fons Bosman; Marijke Verhaeghe; C Russell Middaugh
Journal:  J Pharm Sci       Date:  2009-09       Impact factor: 3.534

9.  Use of a folding model and in situ spectroscopic techniques for rational formulation development and stability testing of monoclonal antibody therapeutics.

Authors:  Gauri Rao; Vandana Iyer; Matthew P Kosloski; Dipak S Pisal; Eunkyoung Shin; C Russell Middaugh; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2010-04       Impact factor: 3.534

10.  Dynamic fluctuations of protein-carbohydrate interactions promote protein aggregation.

Authors:  Vladimir Voynov; Naresh Chennamsetty; Veysel Kayser; Bernhard Helk; Kurt Forrer; Heidi Zhang; Cornelius Fritsch; Holger Heine; Bernhardt L Trout
Journal:  PLoS One       Date:  2009-12-23       Impact factor: 3.240

View more
  72 in total

1.  Rapid quantitative analysis of monoclonal antibody heavy and light chain charge heterogeneity.

Authors:  Ram P Vanam; Michael A Schneider; Michael S Marlow
Journal:  MAbs       Date:  2015-08-25       Impact factor: 5.857

2.  Rational design of therapeutic mAbs against aggregation through protein engineering and incorporation of glycosylation motifs applied to bevacizumab.

Authors:  Fabienne Courtois; Neeraj J Agrawal; Timothy M Lauer; Bernhardt L Trout
Journal:  MAbs       Date:  2016       Impact factor: 5.857

3.  Improved antibody production in Chinese hamster ovary cells by ATF4 overexpression.

Authors:  Ahmad M Haredy; Akitoshi Nishizawa; Kohsuke Honda; Tomoshi Ohya; Hisao Ohtake; Takeshi Omasa
Journal:  Cytotechnology       Date:  2013-09-13       Impact factor: 2.058

4.  Engineering of Yeast Glycoprotein Expression.

Authors:  Charlot De Wachter; Linde Van Landuyt; Nico Callewaert
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

Review 5.  Modulating carbohydrate-protein interactions through glycoengineering of monoclonal antibodies to impact cancer physiology.

Authors:  Austin Wt Chiang; Shangzhong Li; Philipp N Spahn; Anne Richelle; Chih-Chung Kuo; Mojtaba Samoudi; Nathan E Lewis
Journal:  Curr Opin Struct Biol       Date:  2016-09-14       Impact factor: 6.809

6.  Development of a stable low-dose aglycosylated antibody formulation to minimize protein loss during intravenous administration.

Authors:  Sorina Morar-Mitrica; Manasi Puri; Alexandra Beumer Sassi; Joshua Fuller; Ping Hu; George Crotts; Douglas Nesta
Journal:  MAbs       Date:  2015       Impact factor: 5.857

7.  Eliminating antibody polyreactivity through addition of N-linked glycosylation.

Authors:  Gwo-Yu Chuang; Baoshan Zhang; Krisha McKee; Sijy O'Dell; Young Do Kwon; Tongqing Zhou; Julie Blinn; Krissey Lloyd; Robert Parks; Tarra Von Holle; Sung-Youl Ko; Wing-Pui Kong; Amarendra Pegu; Keyun Wang; Kavitha Baruah; Max Crispin; John R Mascola; M Anthony Moody; Barton F Haynes; Ivelin S Georgiev; Peter D Kwong
Journal:  Protein Sci       Date:  2015-05-12       Impact factor: 6.725

Review 8.  Considerations for the Design of Antibody-Based Therapeutics.

Authors:  Dennis R Goulet; William M Atkins
Journal:  J Pharm Sci       Date:  2019-06-04       Impact factor: 3.534

Review 9.  Glycan recognition at the saliva - oral microbiome interface.

Authors:  Benjamin W Cross; Stefan Ruhl
Journal:  Cell Immunol       Date:  2018-08-18       Impact factor: 4.868

10.  Versatile characterization of glycosylation modification in CTLA4-Ig fusion proteins by liquid chromatography-mass spectrometry.

Authors:  Lei Zhu; Qingcheng Guo; Huaizu Guo; Tao Liu; Yingxin Zheng; Peiming Gu; Xi Chen; Hao Wang; Sheng Hou; Yajun Guo
Journal:  MAbs       Date:  2014       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.